Competition is heating up, but questions remain about insurance coverage, drug pricing, copycat drugs and the role of pills in the space.
In this article
The appetite for blockbuster weight loss and diabetes drugs is far from satisfied.
From fresh competition to new uses, the market is quickly vaulting into a new stage of growth. But factors including insurance coverage, pricing, copycat drugs and the development of new pills will ultimately determine how far the treatments will reach.
Eli Lilly
and Novo Nordisk
CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare Conference…
Eli Lilly and Novo Nordisk are preparing to take their rivalry to the next frontier of weight-loss medication: pills.
Growing competition from smaller players is tightening the race for market leaders Novo Nordisk and Eli Lilly as more weight loss…
The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its…
Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for…
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
